Gilead Sciences Inc. to report Q3 results on Oct 26 , Alternate Health Corp. Projected $75 Million in revenue for the next 12 months

0
799

Gilead Sciences Inc. (NASDAQ:GILD) , is expected to beat expectations when it reports third-quarter results on Thursday Oct 26,after hours .

Gilead’s track record is pretty mixed, with the company beating estimates in two of the last four and missing in one two. Last quarter, the company beat expectations by 17.4%. Overall, the company recorded an average positive earnings surprise of 6.4%.

Alternate Health Corp. (OTC:AHGIF) (CSE:AHG) recently projected $75 Million in revenue for the next 12 months starting in Q4 2017. 

“After a strong start to Alternate Health’s 1st year as a public company, we are excited to release our projected revenues for the next year,” says Dr. Michael Murphy, CEO of Alternate Health. “We have assembled a dedicated team of industry veterans and secured key assets across our four business pillars, which will drive significant revenues over the next 12 months.” Source

 

Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewers entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov.In addition, FINRA has published information at its website on how to invest carefully atwww.finra.org/Investors/index.htm.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here